Fintel reports that on February 5, 2025, Leerink Partners upgraded their outlook for Regeneron Pharmaceuticals (NasdaqGS:REGN) from Market Perform to Outperform. Analyst Price Forecast Suggests 42.56% ...

Leerink upgraded Regeneron (REGN) to Outperform from Market Perform with a price target of $834, up from $762. The shares have fallen 35% over ...

Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) had its target price decreased by equities research analysts at Leerink Partners from $980.00 to $862.00 in a research note issued on Tuesday.

Research analysts at Leerink Partnrs lifted their FY2024 earnings estimates for Regeneron Pharmaceuticals in a note issued to ...

In a report released on February 3, Akash Tewari from Jefferies maintained a Buy rating on Regeneron (REGN – Research Report), with a price ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.JzBkOQ-g.js ...

UBS has recently reduced Regeneron Pharmaceuticals Inc (REGN) stock to Neutral rating, as announced on January 16, 2025, according to Finviz. Earlier, on December 10, 2024, BofA Securities had resumed ...

The FDA is to review Sanofi/Regeneron's Dupixent as a treatment for asthma, a new use that could more than double its sales following its previous approval for eczema. Analysts predict peak annual ...

Marion McCourt; Executive Vice President - Commercial; Regeneron Pharmaceuticals Inc. Christopher Fenimore; Chief Financial Officer, Senior Vice President - Finance; Regeneron Pha ...